Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - Žvýkací/dispergovatelná tableta - 5mg - lamotrigin

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - tableta - 25mg - lamotrigin

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - tableta - 100mg - lamotrigin

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - tableta - 50mg - lamotrigin

USA - engelsk - NLM (National Library of Medicine)

glaxosmithkline llc - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 25 mg - lamictal xr is indicated as adjunctive therapy for primary generalized tonic-clonic (pgtc) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. lamictal xr is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (aed). safety and effectiveness of lamictal xr have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. safety and effectiveness of lamictal xr for use in patients younger than 13 years have not been established. lamictal xr is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see boxed warning, warnings and precautions (5.1, 5.3)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy ou

USA - engelsk - NLM (National Library of Medicine)

glaxosmithkline llc - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 25 mg - adjunctive therapy lamictal is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: monotherapy lamictal is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamictal have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamictal is indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [see clinical studies (14.2)] . limitations of use treatment of acute manic or mixed episodes is

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 100 mg - adjunctive therapy: lamictal is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: - partial seizures. - primary generalized tonic-clonic seizures. - generalized seizures of lennox-gastaut syndrome. monotherapy: lamictal is indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamictal have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamictal is indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes w

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 25 mg - adjunctive therapy: lamictal is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: - partial seizures - primary generalized tonic-clonic seizures - generalized seizures of lennox-gastaut syndrome monotherapy: lamictal is indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamictal have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamictal is indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 200 mg - tablet - excipient ingredients: calcium carbonate; hyprolose; aluminium magnesium silicate; sodium starch glycollate; povidone; saccharin sodium; magnesium stearate; flavour - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as ?add-on? therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 50 mg - tablet - excipient ingredients: calcium carbonate; hyprolose; aluminium magnesium silicate; sodium starch glycollate; povidone; saccharin sodium; magnesium stearate; flavour - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as add-on therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.